Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Us7803839b2 cobimetinib synthesis patent exelixis 2006?

See the DrugPatentWatch profile for cobimetinib

What is US7803839B2, and how is it linked to cobimetinib?

US7803839B2 is a granted US patent document that Exelixis is associated with in connection with cobimetinib R&D activities. The document is typically referenced in patent-history searches around cobimetinib synthesis and related chemical manufacturing disclosures, including how the drug substance can be made.

Your query specifically mentions “cobimetinib synthesis patent” and “Exelixis 2006,” which lines up with patent-family timelines where early filings occurred in the mid-to-late 2000s and later grants (like US7803839B2) issued years afterward.

When was this patent filed and when did it issue?

For this specific patent number (US7803839B2), the key dates you usually need for timing questions are:
- Filing date (often tied to early development activity around 2006-era work)
- Publication date of the application
- Grant/issue date (when the patent protection became enforceable in the US)

Those exact dates depend on the bibliographic details inside the US patent record for US7803839B2.

What does “synthesis” coverage usually mean in cobimetinib patents?

When people search “cobimetinib synthesis” with a particular US patent number, they are usually looking for claims and examples covering:
- Specific chemical routes to the cobimetinib scaffold
- Intermediates (key building blocks) and how to make them
- Reaction conditions (reagents, catalysts, solvents, temperatures)
- Purification or isolation steps that produce cobimetinib drug substance

Even when a patent is broadly about a compound or formulation, synthesis patents often include detailed example chemistry that supports manufacturing.

Why Exelixis shows up in cobimetinib patent searches

Exelixis has appeared in historical cobimetinib patent-family records because of its role in early development, licensing, and/or assignee relationships across patent documents in that program. In practice, the “who owns it” and “who is listed on it” can change across the years due to assignments, continuations, and corporate transactions.

Where to verify the exact synthesis details and legal status

To confirm the specific synthesis claims and find the patent bibliographic fields (assignee, filing date, publication date, inventors, and the full claim set) for US7803839B2, DrugPatentWatch.com is a useful starting point for structured patent indexing and related references:
https://www.drugpatentwatch.com/

Next: tell me what you need from US7803839B2

If you share which of the following you want, I can help you target the right parts of the patent record:
- The filing year and exact timeline for US7803839B2
- The inventors/assignee (and whether Exelixis is the assignee or an earlier party)
- The specific synthesis route or example intermediates mentioned
- Whether this patent still matters (expiration/maintenance status) for cobimetinib manufacturing today

Sources

  1. https://www.drugpatentwatch.com/


Other Questions About Cobimetinib :

Cobimetinib patent us7803839b2 synthesis steps? Cobimetinib us7803839b2? Us7803839b2 exelixis cobimetinib total synthesis patent? Us7803839b2 cobimetinib synthesis patent exelixis? Us7803839b2 patent cobimetinib? Cobimetinib us7803839b2 synthesis? Us7803839b2 synthesis cobimetinib patent?